公开(公告)号：US20160160214A1

公开(公告)日：2016-06-09

申请号：US14951424

申请日：2015-11-24

Applicant: CoDa Therapeutics, Inc.

Inventor： David Lawrence Becker ,  Colin Richard Green

IPC: C12N15/113

CPC classification number: C12N15/1138 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/06 ,  A61K31/711 ,  A61K47/34 ,  C12N2310/11 ,  C12N2320/32

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

公开(公告)号：US09193754B2

公开(公告)日：2015-11-24

申请号：US13681383

申请日：2012-11-19

Applicant: CoDa Therapeutics, Inc.

Inventor： David Lawrence Becker ,  Colin Richard Green

IPC: C07H21/04 ,  C07H21/02 ,  A61K31/70 ,  C12N15/11 ,  C12N15/113 ,  A61K31/711 ,  C12Q1/68

CPC classification number: C07H21/04 ,  A61K31/711 ,  A61K38/00 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2320/32

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

公开(公告)号：US09561311B2

公开(公告)日：2017-02-07

申请号：US14715282

申请日：2015-05-18

Applicant: CoDa Therapeutics, Inc.

Inventor： David Lawrence Becker ,  Colin Richard Green ,  Bradford James Duft

IPC: C07H21/04 ,  C07H21/02 ,  A61K39/395 ,  A61K48/00 ,  A61L31/16 ,  A61L17/00 ,  A61L27/54 ,  A61L31/08 ,  A61L31/10

CPC classification number: A61K38/08 ,  A61K9/0051 ,  A61K38/10 ,  A61K38/385 ,  A61L17/005 ,  A61L27/54 ,  A61L31/08 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/25 ,  A61L2300/252 ,  A61L2300/258 ,  A61L2300/432 ,  A61L2300/602 ,  A61L2300/606 ,  A61L2300/608

Abstract: Medical devices comprising an anti-connexin agent suitable for introduction into a subject.

Abstract translation: 包括适合引入受试者的抗连接蛋白剂的医疗装置。

公开(公告)号：US20130079388A1

公开(公告)日：2013-03-28

申请号：US13681383

申请日：2012-11-19

Applicant: CODA THERAPEUTICS, INC.

Inventor： David Lawrence Becker ,  Colin Richard Green

IPC: C07H21/04

CPC classification number: C07H21/04 ,  A61K31/711 ,  A61K38/00 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2320/32

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

Abstract translation: 包含至少一种连接蛋白的反义多核苷酸与药学上可接受的载体或载体的治疗和/或化妆品制剂可用于连接蛋白表达的位点特异性下调，特别是在减少神经元细胞死亡，伤口愈合， 减少炎症，减少瘢痕形成和皮肤复原及增厚。

公开(公告)号：US10201590B2

公开(公告)日：2019-02-12

申请号：US15012732

申请日：2016-02-01

Applicant: CoDa Therapeutics, Inc.

Inventor： Colin Richard Green ,  David Lawrence Becker

IPC: A61K38/08 ,  A61K38/10 ,  A61K38/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/705 ,  A61K31/70 ,  C12N15/115

Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use for treatment of cardiovascular, vascular, neurological, for wounds and for other indications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication or prevention of hemichannel opening is desirable.

公开(公告)号：US09738892B2

公开(公告)日：2017-08-22

申请号：US14642582

申请日：2015-03-09

Applicant: CoDa Therapeutics, Inc.

Inventor： David Lawrence Becker ,  Colin Richard Green ,  Bradford James Duft

IPC: A61K48/00 ,  C07H21/02 ,  C07H21/04 ,  C12N15/113 ,  A61K31/7088 ,  A61K45/06

CPC classification number: C12N15/113 ,  A61K31/7088 ,  A61K45/06 ,  A61L15/44 ,  A61L26/0066 ,  A61L2300/258 ,  A61L2300/432 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/315 ,  Y02A50/423

Abstract: Treatment of fibrosis and fibrotic diseases, disorders, and conditions, and associated methods, compositions, formulations and articles.

公开(公告)号：US10465188B2

公开(公告)日：2019-11-05

申请号：US14833041

申请日：2015-08-21

Applicant: AUCKLAND UNISERVICES LIMITED ,  CODA THERAPEUTICS, INC.

Inventor： Colin Richard Green ,  Yeri Kim ,  Anthony Phillips ,  Bradford James Duft

IPC: C07H21/04 ,  C12N15/113 ,  A61K38/08 ,  A61K38/39 ,  A61K9/00 ,  A61K31/352 ,  A61K31/713 ,  A61K38/10 ,  A61K45/06 ,  A61K31/167 ,  A61K31/195 ,  A61K31/382 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/575 ,  A61P27/02

Abstract: The inventions relate to compositions and articles of manufacture comprising connexin modulators, pannexin modulators, gap junction modulators, hemichannel modulators, and pannexin channel modulators and their use, alone or in combination, in treating ocular and other disorders.

公开(公告)号：US10174316B2

公开(公告)日：2019-01-08

申请号：US14467978

申请日：2014-08-25

Applicant: CoDa Therapeutics, Inc.

Inventor： Wilda Laux ,  Colin Richard Green

IPC: C07H21/02 ,  C07H21/04 ,  A61K31/70 ,  C12N15/113 ,  C12N15/11 ,  A61K31/7105 ,  A61K31/711 ,  C12N5/00

Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.

公开(公告)号：US09932592B2

公开(公告)日：2018-04-03

申请号：US14951424

申请日：2015-11-24

Applicant: CoDa Therapeutics, Inc.

Inventor： David Lawrence Becker ,  Colin Richard Green

IPC: C07H21/02 ,  C07H21/04 ,  A61K31/70 ,  C12N15/113 ,  A61K31/711 ,  A61K9/00 ,  A61K9/06 ,  A61K47/34 ,  C12N5/00

CPC classification number: C12N15/1138 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/06 ,  A61K31/711 ,  A61K47/34 ,  C12N2310/11 ,  C12N2320/32

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

公开(公告)号：US09637745B2

公开(公告)日：2017-05-02

申请号：US14709382

申请日：2015-05-11

Applicant: CoDa Therapeutics, Inc.

Inventor： David Lawrence Becker ,  Colin Richard Green ,  Bradford James Duft

IPC: A61K31/70 ,  C07H21/02 ,  C07H21/04 ,  C12N15/113 ,  A61K31/7105 ,  C12Q1/68

CPC classification number: C12N15/1138 ,  A61K31/7105 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/35

Abstract: Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles.